Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.37 | $382.20 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 2 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,678 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 14, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.37 | $414.05 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 2 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,120 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 14, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.37 | $382.20 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 2 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,602 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 13, 2019 Filed Jun 21, 2019 21:26 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,701 | $6.25 | $10,631.25 |
DisclosureSEC source: 0001209191-19-038591 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,388 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.15, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.30 to $6.20, inclusive. Read SEC document |
| June 13, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.32 | $316.00 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 21 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,104 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 13, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.42 | $385.20 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 1 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,618 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 13, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.42 | $417.30 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 1 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,012 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 13, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.42 | $385.20 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 1 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,542 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.28 | $408.20 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 30 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,867 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.29 | $377.40 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 30 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,482 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,462 | $6.11 | $8,932.82 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 12 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,089 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F14 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.21 to $6.11, inclusive. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.29 | $377.40 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 30 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,558 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.32 | $410.80 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 29 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,802 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.32 | $379.20 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 29 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,422 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 942 | $6.21 | $5,849.82 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 11 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,551 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F13 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.16, inclusive. Read SEC document |
| June 11, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.32 | $379.20 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 29 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,498 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 11, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.23 | $311.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 20 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,054 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 10, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.08 | $395.20 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 28 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,737 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 10, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.09 | $365.40 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 28 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,362 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 10, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 3,549 | $6.03 | $21,400.47 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 10 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,493 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F12 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.12 to $5.90, inclusive. Read SEC document |
| June 10, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.09 | $365.40 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 28 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,438 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 07, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.06 | $393.90 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 27 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,672 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 07, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.07 | $364.20 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 27 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,302 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 07, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,278 | $5.99 | $13,645.22 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 9 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,042 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F11 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.15 to $5.86, inclusive. Read SEC document |
| June 07, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.07 | $364.20 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 27 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,378 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 07, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 65 | $6.28 | $408.20 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 19 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,004 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 06, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.37 | $414.05 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 26 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,607 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 06, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.38 | $382.80 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 26 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,242 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 06, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,495 | $6.22 | $9,298.90 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 8 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,320 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F10 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.29 to $6.15, inclusive. Read SEC document |
| June 06, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.38 | $382.80 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 26 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,318 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 05, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 55 | $6.66 | $366.30 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 25 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,542 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 05, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 50 | $6.67 | $333.50 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 25 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,182 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 05, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,500 | $6.55 | $16,375.00 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 7 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,815 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F9 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $6.43, inclusive. Read SEC document |
| June 05, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 50 | $6.67 | $333.50 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 25 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,258 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 04, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.59 | $428.35 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 24 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,487 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 04, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.60 | $396.00 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 24 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,132 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 04, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,300 | $6.46 | $8,398.00 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 6 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,315 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F8 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.55 to $6.37, inclusive. Read SEC document |
| June 04, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.60 | $396.00 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 24 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,208 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 04, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.49 | $324.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 18 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,939 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 03, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.49 | $421.85 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 23 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,422 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 03, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 23 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,072 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| June 03, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,120 | $6.33 | $7,089.60 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,615 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.25, inclusive. Read SEC document |
| June 03, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 23 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 31, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.56 | $426.40 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 22 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,357 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 31, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.57 | $394.20 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 22 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762,012 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 31, 2019 Filed Jun 14, 2019 21:22 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 742 | $6.46 | $4,793.32 |
DisclosureSEC source: 0001209191-19-037202 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,735 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.68 to $5.86, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.48 to $6.45, inclusive. Read SEC document |
| May 31, 2019 Filed Jun 14, 2019 21:20 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.57 | $394.20 |
DisclosureSEC source: 0001209191-19-037200 · doc4.xml · nonDerivative · entry 22 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,088 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 31, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.47 | $323.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 17 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,889 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 30, 2019 Filed Jun 14, 2019 21:22 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.58 | $427.70 |
DisclosureSEC source: 0001209191-19-037204 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,292 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| May 30, 2019 Filed Jun 14, 2019 21:21 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.58 | $394.80 |
DisclosureSEC source: 0001209191-19-037201 · doc4.xml · nonDerivative · entry 21 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,761,952 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.